Full Fasting for Health & Longevity

Created on 10/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Full fasting, an old healing practice, means going without all food for a day to several weeks while drinking water. Weight loss is reliable; repeated short fasts roughly match daily calorie restriction. Other benefits rest mostly on studies without comparison groups; blood-test gains tend to fade within months. Costs include fatigue, muscle loss, a temporary cholesterol rise and sharply higher danger with diabetes or blood-pressure drugs. Long-term value remains unproven. (Full Review)

Protocol

Short full fast
24–36 hours
Water-only; alternate-day protocols repeat zero-calorie days
Five-day water-only fast
5 days
Water, salt and minerals allowed; refeeding at 30%, 60% and 100% of energy needs on days 6–8
Supervised prolonged water-only fast
Median 7 days (range 2–41)
Short fruit-and-vegetable prefast; refeeding for half the fast length on a plant-based diet
Time to effect
Weight
Within days
Rapid loss with zero energy intake
Blood pressure
Within days
Uncontrolled case series report larger falls after about 10–14 days of water-only fasting
Fuel switch
Days 3–6
Switch from glucose to ketone fuel stabilized

Benefits

Contraindications
  • People meeting NICE refeeding high-risk criteria (such as BMI under 16 kg/m², unintentional weight loss over 15% in 3–6 months, or low potassium, phosphate or magnesium)
  • People taking SGLT2 inhibitors who cannot withhold them
  • People with a prolonged QTc or prior torsade de pointes (for long fasts)
  • Pregnant or breastfeeding women (inferred; no human data)
  • People with type 1 diabetes (inferred; no human data on full fasting)
  • People with a current or past eating disorder (inferred; no human data)
  • People with advanced kidney or liver disease (inferred; no human data)
  • Children and adolescents (inferred; no human data)
Key Interactions
  • Insulin and sulfonylureas (insulin-releasing drugs: glyburide, glipizide): Low blood sugar
  • Metformin (a first-line glucose-lowering drug): Low blood volume, low blood pressure and kidney impairment
  • Acetaminophen (paracetamol), over the counter: Liver injury
  • Alcohol: Low blood sugar
  • Warfarin: Higher warfarin exposure and bleeding risk
  • Caffeine, metoprolol, midazolam and omeprazole: Slightly shorter drug action
  • Lithium: Rising lithium levels and toxicity
  • NSAIDs (nonsteroidal anti-inflammatory drugs: ibuprofen, naproxen), over the counter and prescription: Reduced kidney blood flow and kidney injury
  • Antihypertensives (blood-pressure-lowering drugs: lisinopril, amlodipine): Additive blood pressure fall and near-fainting
  • Thiazide and loop diuretics (drugs increasing urine output: hydrochlorothiazide, furosemide): Compounded dehydration, low blood sodium and low blood potassium
Theoretical (inferred from mechanism)
  • Glucose-lowering supplements (berberine, chromium): Additive low blood sugar
  • Blood-pressure-lowering supplements (garlic extract, hawthorn): Additive low blood pressure and near-fainting
  • Fat-soluble vitamins and fish oil (vitamin D, omega-3 capsules): Poor absorption without dietary fat
  • Sauna and hot baths: Additive dehydration and near-fainting

Risk & Side Effects

  • High:
  • Medium: Rise in LDL and total cholesterol during the fast
  • Low: Fatigue, insomnia, nausea, headache and near-fainting; electrolyte disturbances and dehydration; hyperuricemia; heart-rhythm disturbances and death in very long fasts; starvation ketoacidosis; refeeding syndrome and Wernicke encephalopathy; lean mass loss
  • Speculative: Inflammatory and platelet activation; organ-level protein shifts of unknown consequence

Monitoring

Marker Target Why
Sodium 135–145 mmol/L Safety: low blood sodium stops the fast
Potassium 3.5–5.0 mmol/L Safety: low values signal refeeding risk
Phosphate 2.5–4.5 mg/dL Safety: falls on refeeding
Magnesium 1.7–2.2 mg/dL Safety: falls during long fasts
Uric acid 3.5–7.2 mg/dL Safety: expected to rise; matters with gout
Creatinine 0.6–1.3 mg/dL Safety: kidney function
Glucose 70–99 mg/dL fasting Expected to fall; safety with diabetes drugs
Beta-hydroxybutyrate Below 0.4 mmol/L Expected to rise; marks adherence
LDL cholesterol No established target during a fast; compare post-refeeding value with own baseline Expected to rise
Blood pressure Below 120/80 mmHg Expected to fall; safety for low blood pressure
QTc on ECG 450 ms or less in men, 460 ms or less in women Safety: prolongation precedes arrhythmia
Fat-free mass No established target; track change from own baseline Expected to fall, then recover
Chloride Not specified in the ER Safety: paired with sodium

Cadence: Baseline before a multi-day fast; during fasts longer than 3 days, blood pressure and symptoms daily, electrolytes every 2–3 days, regular ECGs in very long fasts; after refeeding, lipids, uric acid and body composition at 2–4 weeks and 3 months

Qualitative Assessment

  • Energy level and fatigue across fasting days
  • Sleep quality and night waking
  • Hunger intensity, which typically fades after the first days
  • Dizziness or near-fainting on standing
  • Mood and perceived stress
  • Mental clarity and concentration
  • Palpitations or irregular heartbeat